$VERA News

Vera Moves Up Key FDA Review Timeline for Kidney Disease Drug, Expects Critical Trial Results in Third Quarter of 2026

Vera Therapeutics: Strong IgAN Data, But Differentiation Is Still Pending

Evercore ISI Group Maintains Outperform on Vera Therapeutics, Lowers Price Target to $91

Vera Therapeutics Q1 EPS $(1.69) Misses $(1.34) Estimate

Wolfe Research Upgrades Vera Therapeutics to Outperform, Announces $88 Price Target

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics, Inc. (VERA) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Vera Therapeutics Appoints Christopher Hite to Board of Directors

HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Raises Price Target to $110

Does FDA Priority Review And Phase 3 Win For Atacicept Redefine The Bull Case For Vera (VERA)?

Vera Therapeutics Q4 EPS $(1.39) Misses $(1.31) Estimate

Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results

Vera Therapeutics to Participate at Upcoming Investor Conferences

Vera Therapeutics: Hold Rating Based On Potential For Atacicept In IgAN (Rating Downgrade)

Analysts Bullish on Vera Therapeutics (VERA) Amid New Commercial Chief Appointment

Atacicept’s Potential Approval Drives Favorable Views on Vera Therapeutics (VERA)

Vera Therapeutics, Inc. (VERA): A Bull Case Theory

Is Vera’s New Commercial Chief And Atacicept Launch Push Altering The Investment Case For Vera Therapeutics (VERA)?

Vera Therapeutics Readies Atacicept Launch As New CCO Joins, Valuation Lags

Is Vera Therapeutics (VERA) One of the Best High Short Interest Stocks with Biggest Upside Potential?